Scarica l'app Stockscreener
3.14
3.63%
0.11
Dopo l'orario di chiusura:
3.07
-0.07
-2.23%
Sophia Genetics Sa Borsa (SOPH) Ultime notizie
Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q1 2025 Result - Yahoo Finance
Sophia Genetics SA expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Promising Penny Stocks To Consider In April 2025 - simplywall.st
SOPHia Genetics expands testing partnership with AstraZeneca - MSN
SOPHiA Genetics (SOPH) Expands Liquid Biopsy Collaboration with AstraZeneca - GuruFocus
SOPHiA GENETICS Expands Global Collaboration With AstraZeneca To Advance Liquid Biopsy Testing - Nasdaq
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR – Company AnnouncementFT.com - Financial Times
SOPHiA GENETICS and AstraZeneca Scale Breakthrough Liquid Biopsy Testing to 30 Global Centers - Stock Titan
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR - Barchart.com
SOPHiA GENETICS SA's (NASDAQ:SOPH) market cap touched US$204m last week, benefiting both individual investors who own 51% as well as institutions - simplywall.st
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 - marketscreener.com
SOPHiA GENETICS Q1 2025 Earnings: AI Healthcare Leader Reports Financial Results May 6 - Stock Titan
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatili - GuruFocus
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatility - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM Platform and its Liquid Biopsy Capabilities - MarketScreener
SOPHiA GENETICS Partners With Precision for Medicine - marketscreener.com
Major AI Breakthrough: SOPHiA GENETICS Partners to Transform Clinical Trial Analysis - Stock Titan
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities - MarketScreener
Precision Medicine Software Market: Global Expansion & Growth - openPR.com
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? - Yahoo Finance
Mesoblast (NASDAQ:MESO) & SOPHiA GENETICS (NASDAQ:SOPH) Financial Review - Defense World
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For - Simply Wall St
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC - Barchart
Two Use Cases for AI in Healthcare - Streetwise Reports
March 2025's Promising Penny Stocks To Consider - Simply Wall St
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Precision Medicine Software Market Set for Global Expansion - openPR.com
Sophia Genetics at TD Cowen Conference: AI-Powered Growth Strategy By Investing.com - Investing.com UK
SOPHiA GENETICS : To Present at the NVIDIA GTC AI Conference -March 06, 2025 at 05:30 am EST - Marketscreener.com
BTIG cuts Sophia Genetics stock price target to $5, maintains buy - Investing.com
Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Highlights: Record Customer Growth Amidst ... By GuruFocus - Investing.com Canada
SOPHiA GENETICS Reports 2024 Financial Results - TipRanks
SOPHiA GENETICS Earnings Call: Mixed Results, Optimistic Outlook - TipRanks
Sophia Genetics SA reports results for the quarter ended December 31Earnings Summary - TradingView
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Earnings call transcript: Sophia Genetics Q4 2024 sees slight EPS miss - Investing.com
SOPHiA GENETICS SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
SOPHiA GENETICS : Investor PresentationFebruary 2025 -March 04, 2025 at 06:53 am EST - Marketscreener.com
Sophia Genetics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results - PR Newswire
Principal Financial Group Inc. Sells 26,798 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
SOPHiA GENETICS (SOPH) to Release Quarterly Earnings on Tuesday - The AM Reporter
SOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing - PR Newswire
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing -February 24, 2025 at 04:01 am EST - Marketscreener.com
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing – Company Announcement - Financial Times
NeoGenomics plummets on Q4 2024 bottom line miss, soft EPS guidance - MSN
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025 - Marketscreener.com
SOPHiA GENETICS Earnings Preview: AI Healthcare Leader Sets Stage for 2025 Strategic Outlook - Stock Titan
AI In Bioinformatics Market Outlook 2025-2034: Growth Drivers, Share, And Trends - WhaTech
SOPHiA GENETICS (NASDAQ:SOPH) Shares Down 4.4%Here's What Happened - MarketBeat
0.24%
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):